Mechanisms of glucocorticoid resistance in acute lymphoblastic leukaemia

急性淋巴细胞白血病糖皮质激素抵抗机制

• 批准号: nhmrc : 568695
• 负责人: A/Pr Jeffrey Craig
• 金额: $ 36.54万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/mechanisms-glucocorticoid-resistance-lymphoblastic-leukaemia/77076
• 关键词: Mechanisms; glucocorticoid; resistance; acute; lymphoblastic

Glucocorticoids are extremely active drugs used in the treatment of childhood acute lymphoblastic leukaemia (ALL), yet a proportion of patients respond poorly to therapy and exhibit resistance at relapse. Clinically relevant mechanisms of glucocorticoid resistance are poorly understood, principally due to lack of appropriate experimental models. This project will reveal novel mechanisms of drug resistance in childhood leukaemia and lead to novel therapeutic strategies to improve outcome.

糖皮质激素是用于治疗儿童急性淋巴细胞白血病（ALL）的非常活跃的药物，但一部分患者对治疗反应不佳，并在复发时表现出耐药性。糖皮质激素抵抗的临床相关机制知之甚少，主要是由于缺乏适当的实验模型。该项目将揭示儿童白血病耐药性的新机制，并导致新的治疗策略，以改善结果。